Comparison · NCT04033991-b46c07cc
Participants With mRCC and/or aRCC: First Line Sunitinib Treatment vs Participants With mRCC and/or aRCC: Second Line Axitinib Treatment: Number of Participants With Karnofsky Performance Status (KPS) Less Than 80 Percent (%)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Participants With mRCC and/or aRCC: First Line Sunitinib Treatment vs Participants With mRCC and/or aRCC: Second Line Axitinib Treatment: Number of Participants With Karnofsky Performance Status (KPS) Less Than 80 Percent (%). Trial comparisons, record NCT04033991-b46c07cc. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04033991-b46c07cc
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.143 | 0.118 | 0.173 | wilson | |
| Risk in group 2 | 0.231 | 0.165 | 0.314 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0883 | -0.175 | -0.0158 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.618 | 0.424 | 0.902 | log | |
| Odds ratio, group 1 over group 2 | 0.555 | 0.344 | 0.895 | log | |
Number needed to treat, for one fewer participant with the outcome on Participants With mRCC and/or aRCC: First Line Sunitinib Treatment than on Participants With mRCC and/or aRCC: Second Line Axitinib Treatment | 11.3 | 5.72 | 63.4 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Participants With mRCC and/or aRCC: First Line Sunitinib Treatment | Participants who met the selection criteria, diagnosed with mRCC and/or aRCC, received sunitinib as first-line treatment from 2002 till 30 June 2018, according to normal routine healthcare practice in real-world setting, were included in this reporting arm. Data of these participants were derived from Christie NHS database. | 89 | 622 | OG000 |
| Group 2 | Participants With mRCC and/or aRCC: Second Line Axitinib Treatment | Participants who met the selection criteria, diagnosed with mRCC and/or aRCC, received axitinib as second-line treatment from 2002 till 30 June 2018, according to normal routine healthcare practice in real-world setting, were included in this reporting arm. Data of these participants were derived from Christie NHS database. | 28 | 121 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- OTHER_PRE_SPECIFIED
- Title
- Number of Participants With Karnofsky Performance Status (KPS) Less Than 80 Percent (%)
- Description
KPS: used for rating participant activities of daily living on scale from 0-100, higher score = participant is better able to carry out daily activities. Score range: 100 = normal no complaints; no disease evidence, 90 = able to carry normal activity; minor signs/symptoms of disease, 80 = normal activity with effort; some signs/symptoms, 70 = cares for self; unable to carry on normal activity, 60 = requires occasional assistance, but able to care for most personal needs, 50 = requires considerable assistance and frequent medical care, 40 = disabled; requires special care, assistance, 30 = severely disabled; hospital admission is indicated although death not imminent, 20 = very sick; hospital admission necessary, 10 = moribund; fatal processes progressing rapidly and 0 = dead. The lower the score the worse is survival for most serious illnesses. Here, number of participants with KPS \<80% were reported.
- Time frame
- Baseline (data retrieved and observed retrospectively for approximately 1.2 years)
- Population
- Analysis population included all eligible participants with mRCC and/or aRCC, received sunitinib as first-line treatment and/or axitinib as second-line treatment from 2002 till 30 June 2018.
Source ClinicalTrials.gov
Trial
- Title
- Study of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib.
- NCT number
- NCT04033991
- Phases
- Conditions
- Carcinoma, Renal Cell
- Interventions
- Sunitinib, Axitinib
- Lead sponsor
- Pfizer
- Results first posted
- 2022-02-18
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04033991?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04033991-b46c07cc